Urology Times· @UrologyTimes · X·· 23 hours agoScore70
Body · original
VOLGA at #ESMO2026: Perioperative durvalumab plus neoadjuvant enfortumab vedotin significantly improved EFS and OS in patients with MIBC ineligible for or refusing cisplatin. @tompowles1 https://www.urologytimes.com/view/volga-durvalumab-plus-enfortumab-vedotin-improves-efs-os-in-mibc
94 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA2matched by Presidential Symposium I
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgSource: Urology Times · x.com